Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GSK Seeking Up to $2B Bolt-on Acquisitions in India

publication date: Oct 4, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlaxoSmithKline is looking to complete “smaller” acquisition targets in India in the $500 million to $2 billion range, according to the company’s CEO Andrew Witty. He characterized these transactions as bolt-on additions rather than transformative ones. GSK does not need a large acquisition, he said, because the company already has a well-established presence in India with a recognizable brand name. His comments would seem to apply equally to China, where GSK has been involved in several "smaller" M&A transactions. More details....

Stock Symbol: (NYSE: GSK)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...